Publication of SynAct Pharma AB’s prospectus in connection with the issue ahead of planned listing on Aktietorget

SynAct Pharma AB (“SynAct”) hereby publishes its prospectus on the occasion of the company’s issue of shares prior to the planned listing on Aktietorget.

Prospectus, registration form and teaser

Prospectuses (containing full terms and conditions), teaser and application form are available on the company’s (www.synactpharma.se), Aktietorget’s (www.aktietorget.se) and Sedermera Fondkommission’s (www.sedermera.se) and websites respectively.

Conditions for listing

SynAct is approved for listing on Aktietorget, provided that the Board is supplemented by an independent board member (election is scheduled to take place at the extraordinary general meeting on 30 May 2016), that the share market’s ownership dissemination requirements are met and that a minimum level of SEK 20 million is achieved in the issue.

Financial advisor

Sedermera Fondkommission is acting as financial advisor to Synact in connection with the listing issue.

For further information regarding the issue, please contact:

Sedermera Fondkommission
Telephone: 0431-47 17 00
E-mail: info@sedermera.se

For further information about SynAct Pharma AB, please contact:

Jeppe Øvlesen
CEO, SynAct Pharma AB
Telephone: +45 28 44 75 67
E-mail: joo@synactpharma.com

Henrik Stage
CFO, SynAct Pharma AB
Telephone: +45 40 26 09 00
E-mail: hs@synactpharma.com

SynAct Pharma AB, Company registration number 559058-4826, is a biotech company that conducts research and development in inflammatory diseases via the wholly owned Danish subsidiary, SynAct Pharma ApS. The company has a platform technology based on a new class of drug candidate targeting acute deterioration in chronic inflammatory diseases, with the primary purpose of stimulating natural healing mechanisms. SynAct Pharma’s main focus is on the development of the candidate drug AP1189, which strengthens the body’s own cells and fights flares in inflammation by accelerating recovery and thereby reducing the risk of chronic inflammation deterioration.